AIG1

Summary

AIG1 (androgen induced 1, HGNC:21607) is a protein-coding gene on chromosome 6q24.2, encoding Androgen-induced gene 1 protein (Q9NVV5). Hydrolyzes bioactive fatty-acid esters of hydroxy-fatty acids (FAHFAs), but not other major classes of lipids.

Enables hydrolase activity. Involved in long-chain fatty acid catabolic process. Located in membrane.

Source: NCBI Gene 51390 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 42 total
• MANE Select transcript: NM_016108

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21607
Approved symbol	AIG1
Name	androgen induced 1
Location	6q24.2
Locus type	gene with protein product
Status	Approved
Aliases	dJ95L4.1, AIG-1, FLJ10485
Ensembl gene	ENSG00000146416
Ensembl biotype	protein_coding
OMIM	608514
Entrez	51390

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 9 protein_coding, 1 retained_intron

ENST00000275235, ENST00000357847, ENST00000367596, ENST00000367601, ENST00000447498, ENST00000458219, ENST00000470265, ENST00000494282, ENST00000629020, ENST00000646199

RefSeq mRNA: 23 — MANE Select: NM_016108 NM_001286587, NM_001286588, NM_001286589, NM_001363721, NM_001366344, NM_001366345, NM_001366346, NM_001366347, NM_001366348, NM_001366349, NM_001366350, NM_001366351, NM_001366352, NM_001366353, NM_001366354, NM_001366355, NM_001366356, NM_001366358, NM_001366359, NM_001366361, NM_001366362, NM_001366363, NM_016108

CCDS: CCDS5198, CCDS69215, CCDS69216, CCDS87450, CCDS94013, CCDS94014

Canonical transcript exons

ENST00000357847 — 6 exons

Exon	Start	End
ENSE00001931414	143060889	143061066
ENSE00002225513	143165082	143165183
ENSE00002237822	143284110	143284225
ENSE00003590091	143136835	143136990
ENSE00003728578	143339639	143341058
ENSE00003785805	143333282	143333445

Expression profiles

Bgee: expression breadth ubiquitous, 273 present calls, max score 98.31.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 45.2359 / max 456.3778, expressed in 1789 samples.

FANTOM5 promoters (14 alternative TSS)

Promoter ID	TPM avg	Samples expressed
70229	37.3588	1756
70227	3.2428	1178
70231	1.3691	97
70226	0.7160	353
70233	0.5574	81
70235	0.4837	82
70234	0.4745	75
70237	0.3145	59
70228	0.2588	130
70230	0.1283	54

Top tissues by expression

289 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	98.31	gold quality
right lobe of liver	UBERON:0001114	96.73	gold quality
liver	UBERON:0002107	95.13	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	94.63	gold quality
substantia nigra pars reticulata	UBERON:0001966	94.42	gold quality
substantia nigra pars compacta	UBERON:0001965	94.39	gold quality
islet of Langerhans	UBERON:0000006	94.33	gold quality
jejunal mucosa	UBERON:0000399	93.95	gold quality
prefrontal cortex	UBERON:0000451	93.89	gold quality
spinal cord	UBERON:0002240	93.85	gold quality
lateral nuclear group of thalamus	UBERON:0002736	93.64	gold quality
stromal cell of endometrium	CL:0002255	93.59	gold quality
primary visual cortex	UBERON:0002436	93.57	gold quality
calcaneal tendon	UBERON:0003701	93.55	gold quality
adult organism	UBERON:0007023	93.43	gold quality
renal medulla	UBERON:0000362	93.38	gold quality
Brodmann (1909) area 23	UBERON:0013554	93.25	gold quality
heart right ventricle	UBERON:0002080	93.14	gold quality
corpus callosum	UBERON:0002336	93.06	gold quality
descending thoracic aorta	UBERON:0002345	92.68	gold quality
anterior cingulate cortex	UBERON:0009835	92.67	gold quality
cingulate cortex	UBERON:0003027	92.63	gold quality
thoracic aorta	UBERON:0001515	92.50	gold quality
ascending aorta	UBERON:0001496	92.49	gold quality
heart left ventricle	UBERON:0002084	92.44	gold quality
cardiac ventricle	UBERON:0002082	92.43	gold quality
palpebral conjunctiva	UBERON:0001812	92.36	gold quality
esophagus squamous epithelium	UBERON:0006920	92.32	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	92.12	gold quality
right frontal lobe	UBERON:0002810	92.09	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-10	yes	32.70
E-ANND-3	yes	11.60
E-GEOD-100618	no	182.35
E-GEOD-109979	no	72.34

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

49 targeting AIG1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-433-3P	99.98	69.37	1203
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-489-3P	99.80	66.46	839
HSA-MIR-3913-3P	99.74	66.53	938
HSA-MIR-7154-5P	99.69	70.52	1900
HSA-MIR-651-5P	99.64	68.49	1104
HSA-MIR-4261	99.59	70.30	3415

Literature-anchored findings (GeneRIF, showing 3)

• identified a novel Pirh2-interacting protein, AIG1, by yeast two-hybrid screening and confirmed its interaction with p53 both in vitro and in vivo (PMID:21622095)
• These results indicate that AIG1 and ADTRP are founding members of an evolutionarily conserved class of transmembrane threonine hydrolases involved in bioactive lipid metabolism. (PMID:27018888)
• High AIG1 expression is associated with virulence in clinical isolates of Entamoeba histolytica. (PMID:29554130)

Cross-species orthologs

10 orthologs

Organism	Symbol	Gene ID
danio_rerio	aig1	ENSDARG00000007171
mus_musculus	Aig1	ENSMUSG00000019806
rattus_norvegicus	Aig1	ENSRNOG00000010753
drosophila_melanogaster	CG11601	FBGN0031244
drosophila_melanogaster	CG3625	FBGN0031245
drosophila_melanogaster	CG6149	FBGN0036158
caenorhabditis_elegans		WBGENE00007068
caenorhabditis_elegans		WBGENE00007994
caenorhabditis_elegans		WBGENE00007995
caenorhabditis_elegans		WBGENE00304175

Paralogs (1): ADTRP (ENSG00000111863)

Protein

Protein identifiers

Androgen-induced gene 1 protein — Q9NVV5 (reviewed: Q9NVV5)

Alternative names: Fatty acid esters of hydroxy fatty acids hydrolase AIG1

All UniProt accessions (6): Q9NVV5, A0A2R8YCJ8, Q5T2H0, Q5T2H3, Q5T2H4, Q5THU2

UniProt curated annotations — full annotation on UniProt →

Function. Hydrolyzes bioactive fatty-acid esters of hydroxy-fatty acids (FAHFAs), but not other major classes of lipids. Show a preference for FAHFAs with branching distal from the carboxylate head group of the lipids.

Subcellular location. Cell membrane.

Tissue specificity. Highly expressed in heart, ovary, testis, liver, and kidney, at lower levels in spleen, prostate, brain, skeletal muscle, pancreas, small intestine and colon, and undetected in peripheral blood leukocytes, thymus, lung and placenta. AIG1 expression is higher in hair follicles from males than from females.

Activity regulation. Inhibited by N-hydroxyhydantoin carbamate JJH260 and beta-lactone KC01.

Induction. By dihydrotestosterone (DHT).

Similarity. Belongs to the AIG1 family.

Isoforms (6)

UniProt ID	Names	Canonical?
Q9NVV5-2	1	yes
Q9NVV5-1	2
Q9NVV5-3	3
Q9NVV5-4	4
Q9NVV5-5	5
Q9NVV5-6	6

RefSeq proteins (23): NP_001273516, NP_001273517, NP_001273518, NP_001350650, NP_001353273, NP_001353274, NP_001353275, NP_001353276, NP_001353277, NP_001353278, NP_001353279, NP_001353280, NP_001353281, NP_001353282, NP_001353283, NP_001353284, NP_001353285, NP_001353287, NP_001353288, NP_001353290, NP_001353291, NP_001353292, NP_057192* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006838	ADTRP_AIG1	Family

Pfam: PF04750

Catalyzed reactions (Rhea), 12 shown:

• 9-(9Z-octadecenoyloxy)-octadecanoate + H2O = 9-hydroxy-octadecanoate + (9Z)-octadecenoate + H(+) (RHEA:52048)
• 9-hexadecanoyloxy-octadecanoate + H2O = 9-hydroxy-octadecanoate + hexadecanoate + H(+) (RHEA:52052)
• 12-hexadecanoyloxy-octadecanoate + H2O = 12-hydroxyoctadecanoate + hexadecanoate + H(+) (RHEA:52056)
• 12-(9Z-octadecenoyloxy)-octadecanoate + H2O = 12-hydroxyoctadecanoate + (9Z)-octadecenoate + H(+) (RHEA:52060)
• 13-(9Z-octadecenoyloxy)-octadecanoate + H2O = 13-hydroxy-octadecanoate + (9Z)-octadecenoate + H(+) (RHEA:52064)
• 9-(9Z-hexadecenoyloxy)-octadecanoate + H2O = (9Z)-hexadecenoate + 9-hydroxy-octadecanoate + H(+) (RHEA:52068)
• 12-(9Z-hexadecenoyloxy)-octadecanoate + H2O = 12-hydroxyoctadecanoate + (9Z)-hexadecenoate + H(+) (RHEA:52072)
• 13-(9Z-hexadecenoyloxy)-octadecanoate + H2O = 13-hydroxy-octadecanoate + (9Z)-hexadecenoate + H(+) (RHEA:52076)
• 12-octadecanoyloxy-octadecanoate + H2O = 12-hydroxyoctadecanoate + octadecanoate + H(+) (RHEA:52080)
• 13-octadecanoyloxy-octadecanoate + H2O = 13-hydroxy-octadecanoate + octadecanoate + H(+) (RHEA:52084)
• 5-(9Z-hexadecenoyloxy)-octadecanoate + H2O = 5-hydroxy-octadecanoate + (9Z)-hexadecenoate + H(+) (RHEA:52092)
• 9-octadecanoyloxy-octadecanoate + H2O = 9-hydroxy-octadecanoate + octadecanoate + H(+) (RHEA:52096)

UniProt features (28 total): topological domain 7, splice variant 7, transmembrane region 6, site 2, mutagenesis site 2, sequence conflict 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NVV5-F1	93.92	0.86

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 43 (important for catalytic activity); 134 (important for catalytic activity)

Mutagenesis-validated functional residues (2):

Position	Phenotype
43	loss of hydrolase activity.
134	loss of hydrolase activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 156 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_DN, GOBP_FATTY_ACID_CATABOLIC_PROCESS, BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_DN, MODULE_511, GOBP_LONG_CHAIN_FATTY_ACID_METABOLIC_PROCESS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM1, ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN, GOBP_ORGANIC_ACID_CATABOLIC_PROCESS, TCF11_01, TGANTCA_AP1_C, GOBP_LIPID_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_METABOLIC_PROCESS, GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS, RYTTCCTG_ETS2_B

GO Biological Process (2): long-chain fatty acid catabolic process (GO:0042758), lipid metabolic process (GO:0006629)

GO Molecular Function (2): hydrolase activity (GO:0016787), protein binding (GO:0005515)

GO Cellular Component (3): plasma membrane (GO:0005886), endomembrane system (GO:0012505), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
long-chain fatty acid metabolic process	1
fatty acid catabolic process	1
primary metabolic process	1
catalytic activity	1
binding	1
membrane	1
cell periphery	1
vacuole	1
plasma membrane	1

Protein interactions and networks

STRING

390 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
AIG1	GIMAP2	Q9UG22	589
AIG1	CPA5	Q8WXQ8	586
AIG1	GIMAP7	Q8NHV1	559
AIG1	GIMAP1	Q8WWP7	533
AIG1	RCHY1	Q96PM5	507
AIG1	GIMAP5	Q96F15	494
AIG1	TESPA1	A2RU30	450
AIG1	PMEPA1	Q969W9	448
AIG1	RNF34	Q969K3	442
AIG1	GIMAP4	Q9NUV9	442
AIG1	HIVEP2	P31629	441
AIG1	TP53	P04637	437
AIG1	RBM33	Q96EV2	435
AIG1	POU1F1	P28069	408
AIG1	GIMAP6	Q6P9H5	404

IntAct

19 interactions, top by confidence:

A	B	Type	Score
RCHY1	AIG1	psi-mi:“MI:0915”(physical association)	0.600
AIG1	RCHY1	psi-mi:“MI:0403”(colocalization)	0.600
MEP1B	AIG1	psi-mi:“MI:0915”(physical association)	0.370
AIG1	CCR9	psi-mi:“MI:0915”(physical association)	0.370
AIG1	FZD7	psi-mi:“MI:0915”(physical association)	0.370
AIG1	GPR35	psi-mi:“MI:0915”(physical association)	0.370
AIG1	MC4R	psi-mi:“MI:0915”(physical association)	0.370
CSTL1	DENND11	psi-mi:“MI:0914”(association)	0.350
MAGEA8	METTL15	psi-mi:“MI:0914”(association)	0.350
MGARP	RTL8C	psi-mi:“MI:0914”(association)	0.350
GCGR	GPR89A	psi-mi:“MI:0914”(association)	0.350
SLC19A2	TMEM223	psi-mi:“MI:0914”(association)	0.350
SLC22A4	TMEM131L	psi-mi:“MI:0914”(association)	0.350
SLC2A5	ESYT2	psi-mi:“MI:0914”(association)	0.350
SLC6A12	ESYT2	psi-mi:“MI:0914”(association)	0.350
SLC6A15	EI24	psi-mi:“MI:0914”(association)	0.350

BioGRID (70): AIG1 (PCA), AIG1 (Affinity Capture-MS), AIG1 (Two-hybrid), AIG1 (Affinity Capture-RNA), AIG1 (Two-hybrid), AIG1 (Two-hybrid), AIG1 (Two-hybrid), AIG1 (Two-hybrid), AIG1 (Two-hybrid), AIG1 (Two-hybrid), AIG1 (Two-hybrid), AIG1 (Two-hybrid), AIG1 (Two-hybrid), AIG1 (Two-hybrid), AIG1 (Two-hybrid)

ESM2 similar proteins: A0A1B0GVZ9, A4IFN5, A5PK40, A6NH52, A6NI61, B2LYG4, B2RZC9, B6ID01, D2HKB0, D3ZG27, P86229, Q0VDI3, Q15012, Q15546, Q17QJ2, Q1RLT2, Q2TA01, Q4R4I5, Q4R6E8, Q5H8A4, Q5R7Q1, Q5RAH0, Q5RL79, Q5U3C3, Q5VTY9, Q5ZML7, Q64232, Q6PHN7, Q6QRN8, Q719N3, Q71SV0, Q8BWB6, Q8IY49, Q8N6M3, Q8NFT2, Q8R189, Q8VD53, Q8VDI9, Q8VDR5, Q9CQC4

Diamond homologs: Q5M828, Q60534, Q8C138, Q96IZ2, Q9D8B1, Q9NVV5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

42 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	33
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2319 predictions. Top by Δscore:

Variant	Effect	Δscore
6:143061063:TCTG:T	donor_gain	1.0000
6:143061063:TCTGG:T	donor_loss	1.0000
6:143061064:CTGGT:C	donor_loss	1.0000
6:143061065:TGGT:T	donor_loss	1.0000
6:143061066:GGTAA:G	donor_loss	1.0000
6:143061067:G:GG	donor_gain	1.0000
6:143061067:GT:G	donor_loss	1.0000
6:143136957:G:GT	donor_gain	1.0000
6:143136965:C:G	donor_gain	1.0000
6:143136986:GGGTT:G	donor_gain	1.0000
6:143136987:GGTTG:G	donor_gain	1.0000
6:143136988:GTT:G	donor_gain	1.0000
6:143136991:G:GG	donor_gain	1.0000
6:143165080:A:AG	acceptor_gain	1.0000
6:143165080:AGTTT:A	acceptor_gain	1.0000
6:143165081:G:GG	acceptor_gain	1.0000
6:143165081:GTTT:G	acceptor_gain	1.0000
6:143165081:GTTTG:G	acceptor_gain	1.0000
6:143333268:C:A	acceptor_gain	1.0000
6:143333441:GAAAA:G	donor_gain	1.0000
6:143333442:AAAA:A	donor_gain	1.0000
6:143333443:AAA:A	donor_gain	1.0000
6:143333444:AA:A	donor_gain	1.0000
6:143333444:AAG:A	donor_loss	1.0000
6:143333446:G:GG	donor_gain	1.0000
6:143333446:GTA:G	donor_loss	1.0000
6:143333447:TAA:T	donor_loss	1.0000
6:143339043:G:GT	donor_gain	1.0000
6:143061062:ATCTG:A	donor_gain	0.9900
6:143061064:CTG:C	donor_gain	0.9900

AlphaMissense

1565 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:143061046:T:C	F41L	1.000
6:143061048:C:A	F41L	1.000
6:143061048:C:G	F41L	1.000
6:143165097:T:C	F105L	1.000
6:143165099:C:A	F105L	1.000
6:143165099:C:G	F105L	1.000
6:143165100:T:A	W106R	1.000
6:143165100:T:C	W106R	1.000
6:143061032:G:A	G36E	0.999
6:143061040:T:A	W39R	0.999
6:143061040:T:C	W39R	0.999
6:143061065:T:C	L47P	0.999
6:143136985:G:A	G98R	0.999
6:143136985:G:C	G98R	0.999
6:143136985:G:T	G98W	0.999
6:143165131:T:A	I116K	0.999
6:143165166:T:A	W128R	0.999
6:143165166:T:C	W128R	0.999
6:143284110:C:G	H134D	0.999
6:143333313:T:A	W183R	0.999
6:143333313:T:C	W183R	0.999
6:143061047:T:C	F41S	0.998
6:143061050:T:C	L42P	0.998
6:143136853:T:C	F54L	0.998
6:143136855:T:A	F54L	0.998
6:143136855:T:G	F54L	0.998
6:143136950:G:C	R86P	0.998
6:143165097:T:A	F105I	0.998
6:143165098:T:C	F105S	0.998
6:143165122:G:T	R113I	0.998

dbSNP variants (sampled 300 via entrez): RS1000000816 (6:143288462 C>T), RS1000008913 (6:143154915 T>G), RS1000038448 (6:143240562 C>T), RS1000042624 (6:143217507 A>G), RS1000056236 (6:143211167 A>AGAGT), RS1000060344 (6:143145704 T>C), RS1000062943 (6:143071656 C>A,G,T), RS1000065560 (6:143197109 A>G), RS1000065779 (6:143312993 A>G), RS1000070958 (6:143064940 T>C), RS1000102583 (6:143168304 C>T), RS1000112165 (6:143282141 A>C), RS1000119729 (6:143105456 T>C), RS1000119764 (6:143306545 T>C), RS1000121930 (6:143148805 C>G)

Disease associations

OMIM: gene MIM:608514 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST001320_10	Acute lymphoblastic leukemia (childhood)	5.000000e-06
GCST003518_87	Daytime sleep phenotypes	1.000000e-06
GCST007096_155	Pulse pressure	7.000000e-15
GCST007269_204	Pulse pressure	5.000000e-12
GCST007436_3	Carotid intima media thickness	5.000000e-08
GCST007637_43	Diffusing capacity of carbon monoxide	4.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007828	daytime rest measurement
EFO:0005763	pulse pressure measurement
EFO:0009369	diffusing capacity of the lung for carbon monoxide

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PubChem BioAssay actives

2 with measured affinity, of 2 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(6Z)-6-(2-oxo-4-tridecyloxetan-3-ylidene)hexanamide	1801987: Gel-based ABPP Assay from Article 10.1038/nchembio.2051: “AIG1 and ADTRP are atypical integral membrane hydrolases that degrade bioactive FAHFAs.”	ic50	0.1700	uM
[7-[4-(dimethylamino)benzoyl]-1,3-dioxo-5,6,8,8a-tetrahydroimidazo[1,5-a]pyrazin-2-yl] 4-[2-(4-chlorophenyl)ethyl]piperidine-1-carboxylate	1801987: Gel-based ABPP Assay from Article 10.1038/nchembio.2051: “AIG1 and ADTRP are atypical integral membrane hydrolases that degrade bioactive FAHFAs.”	ic50	0.5000	uM

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, increases expression, affects expression, affects cotreatment	6
Benzo(a)pyrene	affects methylation, decreases expression	5
Aflatoxin B1	affects expression, decreases expression, decreases methylation	3
trichostatin A	affects cotreatment, decreases expression	2
Vehicle Emissions	decreases reaction, increases expression, increases abundance	2
Calcitriol	increases expression	2
Cisplatin	affects expression, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Cyclosporine	decreases expression	2
Particulate Matter	decreases reaction, increases expression, increases abundance	2
aristolochic acid I	decreases expression	1
dicrotophos	decreases expression	1
methyleugenol	decreases expression	1
arsenite	affects binding, increases reaction	1
beta-methylcholine	affects expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, decreases expression, affects cotreatment	1
ICG 001	increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases reaction, increases expression	1
dorsomorphin	affects cotreatment, increases expression, decreases expression	1
bisphenol S	affects cotreatment, increases expression	1
NSC 689534	increases expression	1
bisphenol AF	increases expression	1
Temozolomide	decreases expression	1
Decitabine	affects expression	1
Sunitinib	decreases expression	1
Acetaminophen	decreases expression	1
Atrazine	decreases expression	1
Dexamethasone	increases expression, affects cotreatment	1
Chlorpyrifos	decreases response to substance, decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.